MedTrace Logo

Biomarkers in SCOTland CardiomyopatHy Registry (Bio-SCOTCH)

NCT06446271 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 750

Last updated 2024-07-03

No results posted yet for this study

Summary

Genetic cardiomyopathy is increasingly recognised and can lead to heart failure, arrhythmia and sudden cardiac death. Some gene positive patients have rapidly progressive disease with high rates of heart failure and cardiac transplantation, while others present with SCD. Other gene positive patients will never develop cardiomyopathy. At present, we cannot distinguish between these groups and rely on expensive and labour-intensive surveillance by electrocardiography, echocardiography and sometimes cardiac magnetic resonance imaging.

This study will investigate existing and novel biomarkers (including blood, urine electrocardiographic and imaging) at various stages of disease in patients with a personal or family history of TTN, MYBPC3, LMNA, FLNC or DSP gene variant, which are known to cause cardiomyopathy.

Conditions

  • Cardiomyopathies
  • Genetic Predisposition
  • Cardiomyopathy, Primary

Interventions

DIAGNOSTIC_TEST

Plasma biomarker levels

This study will investigate existing and novel biomarkers (including blood, urine electrocardiographic and imaging) at various stages of disease in patients with a personal or family history of TTN, MYBPC3, LMNA, FLNC or DSP gene variant, which are known to cause cardiomyopathy. Cardiomyopathy will be defined per European Society of Cardiology cardiomyopathy guidelines and heart failure stage will be defined per American Heart Associate guidelines.

Sponsors & Collaborators

  • University of Glasgow

    collaborator OTHER

  • Roche Diagnostics GmbH

    collaborator INDUSTRY

  • NHS Greater Glasgow and Clyde

    lead OTHER

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-26
Primary Completion
2027-03-19
Completion
2027-03-19

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06446271 on ClinicalTrials.gov